Clinical trial / 2013
Microbiota metabolism of dietary L-carnitine produces TMAO and promotes atherosclerosis in mice, with TMAO predicting human cardiac risk.
Researchers investigated intestinal microbiota metabolism of dietary L-carnitine into trimethylamine-N-oxide (TMAO) in humans and mice. Following L-carnitine ingestion, omnivorous human subjects produced more TMAO than vegans or vegetarians through a microbiota-dependent mechanism. In 2,595 subjects undergoing cardiac evaluation, plasma L-carnitine predicted increased risks for prevalent cardiovascular disease and incident major adverse cardiac events, but only with concurrently high TMAO levels. In mice, chronic dietary L-carnitine supplementation altered cecal microbial composition, enhanced TMA and TMAO synthesis, and increased atherosclerosis, which did not occur when intestinal microbiota was concurrently suppressed.
- Study type
- Human challenge and cohort studies combined with animal intervention trials
- Who was studied
- Omnivorous vs. vegan/vegetarian humans, 2,595 cardiac evaluation patients, and mice
- What was measured
- TMAO production, prevalent CVD, incident MACE, and atherosclerosis in mice
THE PAPER
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH, Bushman FD, Lusis AJ, Hazen SL. Nat Med, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.